Compare · NVO vs OCS
NVO vs OCS
Side-by-side comparison of Novo Nordisk A/S (NVO) and Oculis Holding AG (OCS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and OCS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 315.2x OCS ($706.8M).
- Over the past year, NVO is down 22.5% and OCS is down 31.6% - NVO leads by 9.1 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 1 for OCS).
- NVO has more recent analyst coverage (25 ratings vs 10 for OCS).
- Company
- Novo Nordisk A/S
- Oculis Holding AG
- Price
- $50.31-2.25%
- $12.18-3.75%
- Market cap
- $222.81B
- $706.8M
- 1M return
- +15.47%
- +6.56%
- 1Y return
- -22.53%
- -31.59%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 1
- Recent ratings
- 25
- 10
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest OCS
- Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
- SEC Form 6-K filed by Oculis Holding AG
- Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
- Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
- Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
- OCS SHAREHOLDER INVESTIGATION: SueWallSt Investigates Oculis Holding AG for Possible Securities Law Violations
- Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
- Guggenheim initiated coverage on Oculis Holding AG with a new price target
- SEC Form 6-K filed by Oculis Holding AG
- Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors